How is the Polynovo share price managing to push higher today?

Polynovo shares are defying the broader ASX market on Thursday.

| More on:
Team celebrating corporate success screaming with joy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares are outperforming the broader market, currently up 4%
  • The company's chair, David Williams, has picked up another batch of shares
  • It appears Williams, among other insiders, believes that Polynovo shares are currently undervalued

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is hovering in positive territory.

During the first hour of trade, the medical device company's shares soared to an intraday high of $1.34.

However, they have retraced a touch to $1.285, a 4.05% gain on yesterday's closing price.

In comparison, the All Ordinaries Index (ASX: XAO) is 1.44% in the red in what has become another volatile day.

Polynovo chair seizes buying opportunity

Taking advantage of the recent Polynovo share price weakness, the company's chair David Williams has picked up more shares.

According to a company release, Williams has bought 346,193 shares at an average price of $1.2431 apiece. This was conducted via an on-market trade by Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equated to a value of more than $430,300.

Following the latest purchase, Williams now has more than 22.25 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in could reflect that Williams believes Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents. Since then, a number of directors, particularly Williams, have made a series of purchases.

Polynovo share price summary

Despite this month's 15% gain, Polynovo shares have fallen by almost 50% in the past 12 months.

Although, when looking at the year to date, its shares are down around 18%.

Based on today's price, Polynovo presides a market capitalisation of roughly $856.89 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »